Education
About Us
Working with TipRanks
Follow Us
Cencora (COR)
NYSE:COR
COR Stock Chart & Stats
$360.24
$2.86(1.22%)
At close: 4:00 PM EST
$360.24
$2.86(1.22%)
Day’s Range― - ―
52-Week Range$223.92 - $362.00
Previous CloseN/A
Volume440.68K
Average Volume (3M)1.30M
Market Cap
$68.63B
Enterprise Value$63.90B
Total Cash (Recent Filing)$2.23B
Total Debt (Recent Filing)$8.24B
Price to Earnings (P/E)44.5
Beta0.08
Next Earnings
Feb 04, 2026EPS Estimate
4.1Last Dividend Ex-Date
Aug 15, 2025Dividend Yield0.62%
Share Statistics
EPS (TTM)3.84
Shares Outstanding193,877,880
10 Day Avg. Volume1,555,473
30 Day Avg. Volume1,298,008
Financial Highlights & Ratios
PEG Ratio6.89
Price to Book (P/B)34.69
Price to Sales (P/S)0.19
P/FCF Ratio18.90
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue0.20
Enterprise Value/Gross Profit6.59
Enterprise Value/Ebitda15.93
Forecast
1Y Price Target
$374.44Price Target Upside3.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Earnings GuidanceManagement raised its full-year adjusted EPS guidance, indicating confidence in future performance.
Healthcare PerformanceUS Healthcare performance in the quarter was exceptionally strong, with FY3Q segment EBIT growth of 29% driven by robust performance across the distribution business.
Long-term Growth PotentialThe stock is seen as having a durable growth story, with recent weaknesses viewed as overdone relative to this perspective.
Bears Say
Growth GuidanceManagement will likely set its FY26 US HC growth guide in line with its long-term growth targets of 5-8%, which could disappoint investors expecting a higher consensus of 9%.
Potential Earnings ImpactThe loss of FCS and Publix could impact future earnings, despite overall positive growth estimates.
Share Price PerformanceThe lack of upside catalysts in the near term and shares trading near all-time highs suggest shares likely remain range-bound.
Cencora News
COR FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest stock price was $223.92 and its highest was $362.00 in the past 12 months.
What is Cencora’s market cap?
Cencora’s market cap is $68.63B.
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is Feb 04, 2026 which is in 88 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on Nov 05, 2025. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.787 by $0.053.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora pays a Quarterly dividend of $0.55 which represents an annual dividend yield of 0.62%. See more information on Cencora dividends here
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is 4.1.
How many shares outstanding does Cencora have?
Cencora has 193,877,880 shares outstanding.
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of $3.84 in its last earnings report, beating expectations of $3.787. Following the earnings report the stock price went up 2.749%.
Which hedge fund is a major shareholder of Cencora?
Currently, no hedge funds are holding shares in COR
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$374.44 (3.94% Upside)
$374.44 (3.94% Upside)
Blogger Sentiment
Bullish
COR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 16.3%
Last 30 Days ▲ 16.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.03%
12-Months-Change
Fundamentals
Return on Equity
129.89%
Trailing 12-Months
Asset Growth
14.14%
Trailing 12-Months
Company Description
Cencora
Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
COR Company Deck
COR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Cencora reported strong financial performance for fiscal 2025 with significant growth in operating income and EPS. The company raised its long-term guidance and made substantial investments in infrastructure to support future growth. Challenges were noted in the PharmaLex business, resulting in a significant goodwill impairment. However, the overall sentiment is positive due to the strong performance and strategic positioning in the specialty market.View all COR earnings summariesCOR Revenue Breakdown
89.54% U.S. Healthcare Solutions
10.46% International Healthcare Solutions
COR Stock 12 Month Forecast
Average Price Target
$374.44
▲(3.94% Upside)
Technical Analysis
Ownership Overview
6.78% Insiders
28.00% Mutual Funds
0.49% Other Institutional Investors
38.48% Public Companies and Individual Investors
Options Prices
Currently, No data available
---